I. G. Schmidt-Wolf

Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma

Katharina, A. Glasmacher, M. Gorschlueter, 2011, German medical science : GMS e-journal.

Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells.

T. Sauerbruch, A. Glasmacher, I. Schmidt-Wolf, 2001, Haematologica.

Activated T cells and cytokine-induced CD3+CD56+ killer cells

I. Schmidt-Wolf, R. Negrin, G. Schmidt‐Wolf, 1997, Annals of Hematology.

Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield

H. Goldschmidt, P. Sonneveld, A. Glasmacher, 2007, Leukemia.

Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein

P. Breig, L. Lehmann, A. Glasmacher, 2004, European Journal of Clinical Microbiology and Infectious Diseases.

Current clinical and laboratory strategies to augment the efficacy of immunotherapy in multiple myeloma.

A. Glasmacher, C. Ziske, M. Gorschlueter, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.